

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>PHARMA-101</b> U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>10/565322</b>
INTERNATIONAL APPLICATION NO. <b>PCT/GR2004/000039</b>	INTERNATIONAL FILING DATE <b>23 July 2004</b>	PRIORITY DATE CLAIMED <b>30 July 2003 EP</b>
TITLE OF INVENTION <b>SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE</b>		
APPLICANT(S) FOR DO/EO/US <b>Evangelos Karavas, Konstantinos Lioumis, Stavros Politis</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
Items 11 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A preliminary amendment.</li> <li>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> </ol>		

IAP15 Rec'd PCT/PTO 20 JAN 2006

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.51)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/565322		PCT/GR 2004/000039		PHARMA-101	
20. Other items or information:					
The following fees have been submitted				CALCULATIONS PTO USE ONLY	
21. <input type="checkbox"/> Basic national fee (37 CFR 1.492(a))..... \$300				\$	300
22. <input type="checkbox"/> Examination fee (37 CFR 1.492(c))				\$	200
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... \$0					
All other situations..... \$200					
23. <input type="checkbox"/> Search fee (37 CFR 1.492(b))				\$	
If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... \$0					
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... \$100					
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB..... \$400					400
All other situations..... \$500					
TOTAL OF 21, 22 and 23 =					
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
- 100 =	/50 =		x \$250	\$	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	23 - 20 =	3	x \$ 50	\$	150
Independent claims	9 - 3 =	0	x \$200	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	1050
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.				x 0.5	
SUBTOTAL =				\$	525.00
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				+	\$
TOTAL NATIONAL FEE =				\$	525.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$
TOTAL FEES ENCLOSED =				\$	565.00
				Amount to be refunded:	\$
				Amount to be charged	\$

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. \_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- d. ☒ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

AKC PATENTS, LLC  
215 GROVE STREET  
NEWTON, MA 02466  
USA

Customer No: 27769

SIGNATURE

NAME

REGISTRATION NUMBER

*[Handwritten Signature]*

Alike K. Collins

43558



10/565322  
JAP15 Rec'd PCT/PTO 20 JAN 2006  
215 Grove Street  
Newton, MA 02466  
TEL (617) 558-5389  
FAX (617) 332-0371  
www.akcpatents.com

January 20, 2006

**Mail Stop PCT**

Commissioner for Patents  
P.O.Box 1450,  
Alexandria, VA 22313-1450

Attorney Docket No.: PHARMA-101

Presented for filing is a US National patent application submission under 35 U.S.C. 371 of international application PCT/GR2004/000039.

Applicants: EVANGELOS KARAVAS, KONSTANTINOS LIOUMIS, STAVROS  
POLITIS, PHARMATHEN S.A.

Title: SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE  
HYDROCHLORIDE

This application claims the benefit of European Patent application Serial No. EP 03386019.8 filed on July 30, 2003 and entitled "SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE", which is commonly assigned and the contents of which are expressly incorporated herein by reference.

Enclosed are the following papers:

	<u>Pages</u>
Copy of the International Application	29
Search Report	2
Assignment recordation cover sheet	1
Assignment	4
Power of Attorney forms	3
Declaration form	3
A credit card form for the filing fee of \$565.00	
Transmittal Letter to DO/EO/US	3

If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at 617-558-5389

Kindly acknowledge receipt of this application by returning the enclosed postcard.


10/565322

IAP15 Rec'd PCT/PTO 20 JAN 2006

Please send all correspondence to:

AKC Patents  
215 Grove Street  
Newton, MA 02466

Respectfully submitted,



Alike K. Collins, Ph.D.  
Reg. No. 43558  
Enclosures

'EXPRESS MAIL "Mailing Label Number" ED 819442483 US

Date of Deposit \_1/20/2006

Alike K. Collins, Ph.D.,



I hereby certify under 37 CFR 1.10 that this correspondence is being  
Deposited with the United States Postal Service as "Express Mail Post Office to  
Addressee" with sufficient postage on the date indicated above and is addressed to Mail  
Stop PCT, Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450